Skip to content

Clinical study on treating visual fatigue caused by presbyopia with Zhangyanming tablets

A randomized, double-blind, placebo-parallel, multicenter clinical study to evaluate the efficacy and safety of Zhangyanming tablets in the treatment of presbyopia-induced visual fatigue (Gan Shen Yin Xu Pattern)

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300069401
Enrollment
Unknown
Registered
2023-03-15
Start date
2023-03-15
Completion date
Unknown
Last updated
2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Presbyopia-induced visual fatigue

Interventions

Experimental group:Zhangyanming tabletoral, 2 tablets a time, tid
Control group:Zhangyanming mimetic tablet oral, 2 tablets a time, tid

Sponsors

Eye System of Wenzhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Aged 40-65 years (including the critical value), male and female; 2. Meet the diagnostic criteria for presbyopia; 3. Meet the diagnostic criteria of western medicine visual fatigue; 4. Conforming to the TCM standards for syndrome differentiation of eye fatigue (Gan Shen Yin Xu Pattern); 5. During screening, the subjects can be equipped with frames, contact lenses or without lenses, and the corrected binocular far visual acuity >= 0.8 (standard logarithmic visual acuity chart test, decimal record); 6. Women were postmenopausal (>= 12 months after menopause), had undergone surgical sterilization, or consented to use effective contraception during the trial; Women of reproductive age or subjects who have gone through menopause less than 12 months must undergo a blood or urine pregnancy test during the screening period and the results must be negative; 7. Voluntary signing of informed consent.

Exclusion criteria

Exclusion criteria: 1. Visual fatigue not caused by presbyopia, such as esotropia, exotropia (oblique Angle > 20 degree), high anisometropia, conjunctivitis, ptosis; 2. Patients with other eye diseases that may affect drug evaluation, such as glaucoma, uveitis, and severe fundus diseases (such as proliferative diabetic retinopathy, retinal detachment); 3. Patients who underwent corneal refractive surgery, cataract surgery, glaucoma surgery or strabismus surgery within 3 months before enrollment; 4. Dry eye related examinations were performed during screening, and the examination results supported the diagnosis of dry eye, but no corresponding treatment was performed or the patients had been diagnosed with dry eye but had been treated with drugs for less than 1 month;Tests to support the diagnosis of dry eye can be one of the following: (1) Tear film rupture time (TBUT) = 1.5 times the upper limit of normal, SCr > the upper limit of normal); 8. Known or suspected allergic history or severe adverse reaction to the test drug and its excipients, or allergic constitution; 9. Unable to cooperate or unwilling to cooperate because of neurological or mental illness; 10. Participants who had participated in other clinical trials within 3 months before enrollment; 11. Pregnant or lactating women, patients who have family planning in the past six months; 12. According to the judgment of the researcher, it is not suitable to participate in the clinical trial.

Design outcomes

Primary

MeasureTime frame
Visual fatigue symptom score;

Secondary

MeasureTime frame
Amplitude of binocular accommodation (AMP);Negative relative regulation (NRA);Positive relative regulation (PRA);Additional degree of presbyopia (Add);Organized Crime Threat Assessment (OCTA) examination;Short distance time with eyes;Tear film break-up time (TBUT);TCM syndrome score;

Countries

China

Contacts

Public ContactQu Jia

Eye System of Wenzhou Medical University

15622271658@163.com+86 15622271658

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026